{"id":13924,"date":"2022-08-25T12:00:28","date_gmt":"2022-08-25T10:00:28","guid":{"rendered":"https:\/\/www.bm-t.de\/2021\/bmt-investee-partner-oncgnostics-enters-the-chinese-market\/"},"modified":"2022-08-25T15:58:58","modified_gmt":"2022-08-25T13:58:58","slug":"bmt-investee-partner-oncgnostics-enters-the-chinese-market","status":"publish","type":"post","link":"https:\/\/www.bm-t.de\/en\/2022-en\/bmt-investee-partner-oncgnostics-enters-the-chinese-market\/","title":{"rendered":"bm|t Investee-Partner oncgnostics enters the Chinese market"},"content":{"rendered":"<p><strong>The cer\u00advi\u00adcal can\u00adcer screen\u00ading test Gyn\u00adTect is now avail\u00adable to physi\u00adcians and patients in China, the world\u2019s most pop\u00adu\u00adlous coun\u00adtry. The prod\u00aduct is the first approved DNA methy\u00adla\u00adtion test for triage of HPV-pos\u00adi\u00adtive cases in China. Gyn\u00adTect was devel\u00adoped by oncg\u00adnos\u00adtics GmbH and is already approved in Europe.&nbsp;<\/strong><\/p>\n<p>Since 2017, there has been a coop\u00ader\u00ada\u00adtion between oncg\u00adnos\u00adtics GmbH and its Chi\u00adnese part\u00adner GeneoDx, a sub\u00adsidiary of the Sinopharm Group. The Gyn\u00adTect clar\u00adi\u00adfi\u00adca\u00adtion test has now been approved by the Chi\u00adnese National Med\u00adical Prod\u00aducts Admin\u00adis\u00adtra\u00adtion (NMPA). An impor\u00adtant pre\u00adreq\u00adui\u00adsite for this approval was a large-scale, multi-year study involv\u00ading approx\u00adi\u00admately 10,000 par\u00adtic\u00adi\u00adpants. The highly suc\u00adcess\u00adful per\u00adfor\u00admance of Gyn\u00adTect in this study was again proven.<\/p>\n<p>\u201cOur part\u00adners in China have done a remark\u00adable job with their large study. The sub\u00adse\u00adquent approval for the Chi\u00adnese mar\u00adket is an impor\u00adtant mile\u00adstone for both our part\u00adner and our com\u00adpany. All pre\u00adreq\u00adui\u00adsites for sales in China have thus been achieved,\u201d states Dr. Alfred Hansel, Man\u00adag\u00ading Direc\u00adtor of oncg\u00adnos\u00adtics&nbsp;GmbH.<\/p>\n<p><strong>How Gyn\u00adTect&nbsp;works<\/strong><\/p>\n<p>The mol\u00ade\u00adc\u00adu\u00adlar bio\u00adlog\u00adi\u00adcal test Gyn\u00adTect devel\u00adoped by oncg\u00adnos\u00adtics clar\u00adi\u00adfies early whether a patient with an abnor\u00admal find\u00ading after under\u00adgo\u00ading cer\u00advi\u00adcal can\u00adcer screen\u00ading has a pre\u00addis\u00adpo\u00adsi\u00adtion for or already has cer\u00advi\u00adcal car\u00adci\u00adnoma (cer\u00advi\u00adcal can\u00adcer), result\u00ading in the need for prompt treat\u00adment.&nbsp;&nbsp;This screen\u00ading test detects epi\u00adge\u00adnetic changes, so-called methy\u00adla\u00adtions. Merely a cer\u00advi\u00adcal smear, also obtained for thin-layer cytol\u00adogy or HPV test\u00ading, is needed to per\u00adform this test. Gyn\u00adTect has a high sen\u00adsi\u00adtiv\u00adity rate \u2013 to this date all can\u00adcer cases have been detected in stud\u00adies in which it is used. In addi\u00adtion, the test has a very high speci\u00adficity rate: very few women with incon\u00adspic\u00adu\u00adous find\u00adings are Gyn\u00adTect-pos\u00adi\u00adtive. This pos\u00adi\u00adtive aspect has been recon\u00adfirmed by the Chi\u00adnese approval study.<\/p>\n<p><strong>GeneoDx dis\u00adtrib\u00adutes Gyn\u00adTect in China under exclu\u00adsive license<\/strong><\/p>\n<p>\u201cWe are pleased to announce that GeneoDx has received approval for Gyn\u00adTect, the first DNA methy\u00adla\u00adtion-based cer\u00advi\u00adcal can\u00adcer screen\u00ading diag\u00adnos\u00adtic in China. This is a huge mile\u00adstone for GeneoDx, but also for all Chi\u00adnese women now hav\u00ading access to such an inno\u00adv\u00ada\u00adtive prod\u00aduct!\u201d said Xiaokai Xia, Man\u00adag\u00ading Direc\u00adtor of Shang\u00adhai GeneoDx.<\/p>\n<p>China is home to more than 400 mil\u00adlion women between the ages of 25 and 64, all of whom are at risk of devel\u00adop\u00ading cer\u00advi\u00adcal can\u00adcer. More than 100,000 new can\u00adcer cases and nearly 60,000 deaths are reported here annu\u00adally. Gyn\u00adTec\u00adt\u2019s approval means it can now be used in women 30&nbsp;years and older who are infected with high-risk, can\u00adcer-caus\u00ading HPV types. Screen\u00ading stud\u00adies showed that approx\u00adi\u00admately 17% of women in China are infected with one of these types of high-risk HPV. This equates to about 70 mil\u00adlion female patients who need screen\u00ading. How\u00adever, only a small per\u00adcent\u00adage of women with a HPV infec\u00adtion actu\u00adally develop cer\u00advi\u00adcal can\u00adcer. It is pre\u00adcisely these cases that the Gyn\u00adTect test is designed to detect.<\/p>\n<p><strong>Advan\u00adtages of GynTect<\/strong><\/p>\n<p>Gyn\u00adTect pro\u00advides fast and reli\u00adable test results, giv\u00ading affected women the cer\u00adtainty they need in order to appro\u00adpri\u00adately pro\u00adceed with needed care upon receiv\u00ading an abnor\u00admal screen\u00ading result. Risk assess\u00adment is greatly facil\u00adi\u00adtated due to the avoid\u00adance of unnec\u00ades\u00adsary pre\u00adma\u00adture surgery and the increased chances of deter\u00admin\u00ading suc\u00adcess\u00adful ther\u00ada\u00adpeu\u00adtic mea\u00adsures. Accord\u00ading to GeneoDx, the num\u00adber of col\u00adposcopy refer\u00adrals can be reduced by more than 60% when using GynTect.<\/p>\n<p>In addi\u00adtion to numer\u00adous EU coun\u00adtries and the Peo\u00adple\u2019s Repub\u00adlic of China, Gyn\u00adTect is already being mar\u00adketed in Brazil and Mex\u00adico. oncg\u00adnos\u00adtics GmbH con\u00adtin\u00adues to estab\u00adlish fur\u00adther suit\u00adable dis\u00adtri\u00adb\u00adu\u00adtion part\u00adner\u00adships with other coun\u00adtries worldwide.<\/p>\n<p>\u201cThis is another suc\u00adcess for our bm|t port\u00adfo\u00adlio and again demon\u00adstrates the world-class level of the life sci\u00adence clus\u00adter in Jena. We are par\u00adtic\u00adu\u00adlarly pleased that oncg\u00adnos\u00adtics is already in advanced dis\u00adcus\u00adsions with addi\u00adtional part\u00adners for approval in the US.\u201d Says Michael Thiele, Invest\u00adment Man\u00adager of bm|t.<\/p>\n<h4><strong>About oncgnostics GmbH:<\/strong><\/h4>\n<p>Jena-based oncg\u00adnos\u00adtics GmbH spe\u00adcial\u00adizes in the early detec\u00adtion of can\u00adcer. Its tests detect changes char\u00adac\u00adter\u00adis\u00adtic of can\u00adcer cell DNA. Founded in 2012, the com\u00adpany launched the Gyn\u00adTect test for cer\u00advi\u00adcal can\u00adcer diag\u00adnos\u00adtics in 2015. oncg\u00adnos\u00adtics GmbH is also con\u00adduct\u00ading research into other can\u00adcer-type screen\u00ading tests. For detailed infor\u00adma\u00adtion, please visit our web\u00adsite www.oncgnostics.com.<\/p>\n<h4><strong>About GeneoDx and the SINOPHARM Group:<\/strong><\/h4>\n<p>GeneoDx is a sub\u00adsidiary of Sinopharm Group (China National Phar\u00adma\u00adceu\u00adti\u00adcal Group Co Ldt.). As one of the coun\u00adtry\u2019s lead\u00ading health\u00adcare com\u00adpa\u00adnies, Sinopharm has built a nation\u00adwide logis\u00adtics and dis\u00adtri\u00adb\u00adu\u00adtion net\u00adwork for phar\u00adma\u00adceu\u00adti\u00adcals, med\u00adical devices and equip\u00adment. Start\u00ading from research and devel\u00adop\u00adment, man\u00adu\u00adfac\u00adtur\u00ading, dis\u00adtri\u00adb\u00adu\u00adtion, tech\u00adni\u00adcal and finan\u00adcial ser\u00advices, the Group cov\u00aders the whole range of the indus\u00adtry. Sinopharm is ranked 80&nbsp;in the global for\u00adtune list, has more than 120 000 employ\u00adees and rev\u00adenues of 103.2 Mrd Euro in&nbsp;2021.<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The cer\u00advi\u00adcal can\u00adcer screen\u00ading test Gyn\u00adTect is now avail\u00adable to physi\u00adcians and patients in&nbsp;China.<\/p>\n","protected":false},"author":2,"featured_media":13918,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[216],"tags":[171,176,201,210],"class_list":["post-13924","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-2022-en","tag-thuringia","tag-bm-t-en","tag-presse","tag-investeepartner"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts\/13924","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/comments?post=13924"}],"version-history":[{"count":0,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts\/13924\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/media\/13918"}],"wp:attachment":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/media?parent=13924"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/categories?post=13924"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/tags?post=13924"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}